Description Genotype/phenotype of patients with Parkinson’s disease. Report of an Argentinean cohort included in the LARGE PD Consortium.
Objective: To characterize the genetic and phenotypic profile of Argentinean Parkinson's patients and contribute to the understanding of the genetic heterogeneity of this disease. Background:…Utilization of Skin Punch Biopsy for the Diagnosis of Alpha-synucleinopathy in Clinical Practice
Objective: To understand the use of skin punch biopsies for diagnosis and management of α-synucleinopathy within a large medical system. Background: Skin punch biopsy has…Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models
Objective: This study investigates the potential neuroprotective effects of several mushroom extracts in PD in-vitro models. Background: Parkinson's disease, a progressive condition, involves dysfunction or…TM9SF2 Knockdown Decreases Pathological Alpha-synuclein Aggregation In Vivo
Objective: To determine whether knockdown of transmembrane 9 super family 2 (TM9SF2) decreases the formation of alpha-synuclein inclusions and toxicity to nigral neurons in the…Serum Alpha-Synuclein Levels Are Decreased in Patients with Restless Legs Syndrome and Restored by Intravenous Iron Therapy in Correlation with Ferritin
Objective: To determine potential connection between serum Alpha-synuclein (α-syn) concentrations and restless legs syndrome (RLS), and explore the impact of intravenous (IV) iron supplementation on serum…New α-Synuclein Strain Biomarker in Parkinson’s Disease and Related Dementia
Objective: Biomarker development for Parkinson’s disease and related dementia. Background: α-Synuclein (α-syn) strains can serve as discriminators of Parkinson's disease (PD) from other α-synucleinopathies. However,…The Effect of Modulating Alpha-synuclein Aggregation on Clinical Outcome in the Presence of Standard-of-care Dopaminergic Therapy in Parkinson’s Disease. A Quantitative Systems Pharmacology Approach.
Objective: Understanding the biological link between alpha-synuclein biomarker changes and clinical outcome using computer simulation. Background: A number of disease modifying therapeutic interventions focused on…Exploring the Therapeutic Target for Lewy Body Disease using gba1 Knock-out Medaka
Objective: This study was performed to explore the therapeutic target for Lewy body disease. Background: Lewy body disease (LBD), including Parkinson's disease and diffuse Lewy…Prevalence of Phosphorylated Alpha-Synuclein in Skin Biopsies of Essential Tremor Patients
Objective: To examine the prevalence of phosphorylated alpha-synuclein in nerve fibers in patients with essential tremor (ET) and ET plus. Background: Although Essential Tremor (ET)…Visual Hallucinations and α-Synuclein Oligomers in Dementia with Lewy Bodies (DLB)
Objective: To determine whether visual hallucinations (VH) in dementia with Lewy bodies (DLB) are associated with α-synuclein oligomers. Background: It is not known whether VH…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 60
- Next Page »